Aurobindo Pharma zoomed 19.4 per cent to close at Rs 135.10, after receiving approval from the USFDA to manufacture and market sertraline hydrochloride. It is the generic equivalent to Pfizer’s Zoloft, used for the treatment of depressive disorders.
This is Aurobindo’s 82nd abbreviated new drug application (ANDA) approval from the USFDA. The stock hit an intraday high of Rs 137 and a low of Rs 116, with trading volumes of 1,80,804 shares. The scrip is up 33 per cent from its 52-week low of Rs 101.60 (November 6, 2008).